PARTNER 3 试验:低危患者 TAVR 与外科换瓣 7 年瓣膜耐久性事后分析
基于 PARTNER 3 随机临床试验的事后分析,纳入接受瓣膜植入的低危症状性重度主动脉瓣狭窄患者(TAVR 495 例、外科 453 例),随访至 7 年。TAVR 与外科在 SVD 相关 BVD、全因 BVF、SVD 相关 BVF 及再干预率上均较低且相近,但 TAVR 组血栓相关 BVD 更多见。
要点
- 低危患者 7 年 SVD 相关 BVD、全因 BVF 与再干预率在 TAVR 与外科间相近且均较低。
- TAVR 组 2/3 期血栓相关 BVD 发生率更高(5.2% vs 0.9%),多发生于 3 年内,极少进展为 BVF。
- 7 年时无全因 BVF 生存比例 TAVR 73.4%、外科 74.8%,差异无统计学意义。
核心结论
- 低危症状性重度主动脉瓣狭窄患者中,TAVR 与外科换瓣 7 年瓣膜耐久性相当且持久,SVD、全因 BVF 及再干预率均低且相近。
研究设计与样本
- PARTNER 3 随机临床试验的事后分析,2016 年 3 月至 2017 年 10 月在美国和加拿大 71 个中心入组 1000 例患者。
- 本分析纳入所有接受瓣膜植入者,共 495 例 TAVR(SAPIEN 3 球囊扩张瓣)与 453 例外科换瓣(任意市售瓣膜)。
- 末次 7 年随访于 2025 年 3 月完成,累积发生率以死亡为竞争风险计算。
主要发现
- 2/3 期 SVD 相关 BVD:TAVR 7.3% vs 外科 7.6%(HR 0.96,95%CI 0.59-1.57,P=.88)。
- 全因 BVF:6.9% vs 7.5%(HR 0.91,95%CI 0.55-1.49,P=.69);SVD 相关 BVF:3.9% vs 5.3%(HR 0.72,95%CI 0.39-1.36,P=.31)。
- 瓣膜再干预:6.0% vs 5.5%(HR 1.09,95%CI 0.62-1.90,P=.77)。
- 2/3 期血栓相关 BVD:TAVR 5.2% vs 外科 0.9%(HR 5.52,95%CI 1.92-15.85,P<.001),多数事件发生在 3 年内,少数进展为 BVF。
- 2/3 期感染性心内膜炎相关 BVD:0.4% vs 0.5%(HR 0.85,95%CI 0.12-6.07,P=.87);7 年无全因 BVF 生存比例 73.4%(331/451)vs 74.8%(288/385),P=.69。
关键数值与推荐
- 7 年时 671 例存活在研患者中 537 例(80.0%)可行超声心动图分析。
- 研究人群平均(SD)年龄 73.5(6.0)岁,男性 657 例(69.3%)。
临床怎么用
- 对低危重度主动脉瓣狭窄患者,7 年数据支持 TAVR 与外科换瓣耐久性相当,可用于瓣膜置换策略的医患讨论。
- TAVR 后应关注血栓相关 BVD,尤其术后 3 年内,但多数未进展为 BVF。
局限性
- 本研究为 PARTNER 3 的事后分析(ad hoc analysis),并非预设的耐久性终点分析。
- 7 年超声心动图分析仅覆盖存活在研患者的 80.0%,存在随访缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: As transcatheter aortic valve replacement (TAVR) is considered for younger and lower-risk populations, the durability of bioprosthetic valves is increasingly important. Limited data exist on long-term (7 years and beyond) valve durability. OBJECTIVE: To report 7-year valve durability outcomes for low-risk patients with symptomatic severe aortic stenosis treated with TAVR vs surgery. DESIGN, SETTING, AND PARTICIPANTS: Between March 2016 and October 2017, a total of 1000 patients were enrolled at 71 centers in the US and Canada and randomized to undergo TAVR vs surgery. The patient population for the present analysis consisted of all patients who underwent valve implantation (495 with TAVR and 453 with surgery). The last 7-year follow-up occurred in March 2025. INTERVENTIONS: Patients were randomized to balloon-expandable TAVR with the SAPIEN 3 valve or surgery with any commercially available valve. MAIN OUTCOMES AND MEASURES: The main outcomes of this analysis were stage 2 or 3 bioprosthetic valve dysfunction (BVD) related to structural valve deterioration (SVD), thrombosis, or endocarditis; all-cause bioprosthetic valve failure (BVF); BVF related to SVD; and aortic valve reintervention at 7 years. Analyses are presented as cumulative incidence rates with death as a competing risk. RESULTS: The mean (SD) age of the study population was 73.5 (6.0) years, and 657 participants (69.3%) were male. Of 671 patients who were still alive and enrolled in the study at 7-year follow-up, 537 (80.0%) were available for echocardiographic analysis. Cumulative incidence rates of stage 2 or 3 SVD-related BVD (7.3% vs 7.6%; hazard ratio [HR], 0.96; 95% CI, 0.59-1.57; P = .88), all-cause BVF (6.9% vs 7.5%; HR, 0.91; 95% CI, 0.55-1.49; P = .69), SVD-related BVF (3.9% vs 5.3%; HR, 0.72; 95% CI, 0.39-1.36; P = .31), and valve reintervention (6.0% vs 5.5%; HR, 1.09; 95% CI, 0.62-1.90; P = .77) were low and similar for TAVR and surgery, respectively. Stage 2 or 3 thrombosis-related BVD (subclinical and clinical) occurred more frequently with TAVR (5.2% vs 0.9%; HR, 5.52; 95% CI, 1.92-15.85; P < .001), although most events occurred within 3 years and few progressed to BVF. Rates of stage 2 or 3 endocarditis-related BVD were also low and similar (0.4% in the TAVR group vs 0.5% in the surgery group; HR, 0.85; 95% CI, 0.12-6.07; P = .87). The proportion of patients alive and free of all-cause BVF was 73.4% (331/451) with TAVR vs 74.8% (288/385) with surgery (P = .69). CONCLUSIONS AND RELEVANCE: In this ad hoc analysis of a randomized clinical trial among low-risk patients with symptomatic severe aortic stenosis randomized to TAVR or surgery, both TAVR and surgery demonstrated comparable and sustained valve durability, with low and similar rates of SVD, all-cause BVF, and reintervention through 7 years. These findings may inform discussions of valve replacement strategies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02675114.
引用
- Ternacle J, Hahn RT, Silva I, et al. Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42340728. doi:10.1001/jamacardio.2026.2299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。